Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) EBITDA Margin: 2017-2020

Historic EBITDA Margin for Cogent Biosciences (COGT) over the last 4 years, with Sep 2020 value amounting to -16,020.19%.

  • Cogent Biosciences' EBITDA Margin fell 1485127.00% to -16,020.19% in Q3 2020 from the same period last year, while for Sep 2020 it was -264.14%, marking a year-over-year increase of 12358.00%. This contributed to the annual value of -950.43% for FY2020, which is 80899.00% down from last year.
  • Cogent Biosciences' EBITDA Margin amounted to -16,020.19% in Q3 2020, which was down 1,044.14% from -1,400.19% recorded in Q2 2020.
  • Over the past 5 years, Cogent Biosciences' EBITDA Margin peaked at 15.02% during Q4 2019, and registered a low of -16,020.19% during Q3 2020.
  • Moreover, its 3-year median value for EBITDA Margin was -382.61% (2019), whereas its average is -1,904.33%.
  • Within the past 5 years, the most significant YoY rise in Cogent Biosciences' EBITDA Margin was 29,593bps (2020), while the steepest drop was 1,485,127bps (2020).
  • Over the past 4 years, Cogent Biosciences' EBITDA Margin (Quarterly) stood at -314.74% in 2017, then soared by 8,888bps to -225.86% in 2018, then surged by 24,089bps to 15.02% in 2019, then crashed by 1,485,127bps to -16,020.19% in 2020.
  • Its EBITDA Margin stands at -16,020.19% for Q3 2020, versus -1,400.19% for Q2 2020 and -86.67% for Q1 2020.